The content and form of Yoruba ijala.

In the first part of the thesis, the author starts with a description of the social setting and the nature of Yoruba ijala. Then he makes a quick survey of the constituent elements of the content of Yoruba ijala, and, after expounding the characteristics of both the inner and the outer form of ijala [which lead him to conclude that ijala is a type of oral poetry with a metrical scheme] he records the standards by which ijala-composition and ijala-performance are respectively judged. In the second part of the thesis, the author gives, with English translations and explanatory notes, representative examples of ijala, arranged in classes

The Utilization of Building Information Modeling In Nigerian Construction Industry: Challenges and Prospects

The aim of this research is to appraise the challenges and prospects in the use of Building Information Modeling (BIM) in the construction industry in Nigeria. It analyzed the uses of BIM in the construction industry, determined the stakeholders perception of the benefits, risk and benchmarks in the adoption of BIM in construction practice and process. It examined the extent of its interoperability in bringing together the different participants and processes of construction works for efficiency and effective construction management and timely project delivery. It compared the findings with the same studies carried out and/or currently being carried out in many parts of the world. Primary data were collected through structured questionnaires. The questionnaires were distributed and collected through personal contacts, letters, online groups and e-mails. Direct observation and interviews were made with professionals in the construction industry The secondary data were obtained from the exploration of various relevant literature and previous researches that have been done in relevant areas. A purposive and modified BIM measurement survey was used for this research work to gather the opinion and views of various construction professionals and clients A total of One Hundred and Fifty (150) questionnaires were distributed based on the sample population. One Hundred and Thirty-two (132) questionnaires were retrieved and used to obtain the required information for data. Tools used the purpose of this research include mean score, percentile and inferential method of statistical analysis. The statistical package for social science (SPSS) was basically used to create the frequency tables and the charts. The study showed that the application of BIM is economical and easy leading to improvement, enhanced technical and general management of construction projects which can lead to total control of cost estimates, prompt delivery of projects and quality are the most important key performance indicators in construction

Survey dataset on architect's awareness and adoption of building envelope technologies for energy efficient housing in Lagos State

Low energy houses are forms of housing that use less energy from the design, technologies and building products from any source than a traditional or average contemporary house. The survey dataset examines architect's awareness and adoption of building envelope technologies (BET) for energy efficient housing in Lagos State, Nigeria. The dataset was based on seventy-four (74) returned questionnaires of both registered and non-registered Architects. A multistage sampling that involved cluster sampling and random sampling of architects in Lagos State was adopted. Descriptive statistical tools were used to present the dataset. The dataset contains the intent of promoting energy sustainability by architect while designing their building envelopes, the awareness of the building envelope strategies to adopt, factors influencing their adoption of these strategies, strategies that can be adopted to improve adoption of building envelope technologies for energy efficiency in housing units. The dataset can be used for evolving housing energy policy by decision maker

Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial

Background Tranexamic acid reduces surgical bleeding and decreases mortality in patients with traumatic extracranial bleeding. Intracranial bleeding is common after traumatic brain injury (TBI) and can cause brain herniation and death. We aimed to assess the effects of tranexamic acid in patients with TBI. Methods This randomised, placebo-controlled trial was done in 175 hospitals in 29 countries. Adults with TBI who were within 3 h of injury, had a Glasgow Coma Scale (GCS) score of 12 or lower or any intracranial bleeding on CT scan, and no major extracranial bleeding were eligible. The time window for eligibility was originally 8 h but in 2016 the protocol was changed to limit recruitment to patients within 3 h of injury. This change was made blind to the trial data, in response to external evidence suggesting that delayed treatment is unlikely to be effective. We randomly assigned (1:1) patients to receive tranexamic acid (loading dose 1 g over 10 min then infusion of 1 g over 8 h) or matching placebo. Patients were assigned by selecting a numbered treatment pack from a box containing eight packs that were identical apart from the pack number. Patients, caregivers, and those assessing outcomes were masked to allocation. The primary outcome was head injury-related death in hospital within 28 days of injury in patients treated within 3 h of injury. We prespecified a sensitivity analysis that excluded patients with a GCS score of 3 and those with bilateral unreactive pupils at baseline. All analyses were done by intention to treat. This trial was registered with ISRCTN (ISRCTN15088122), ClinicalTrials.gov (NCT01402882), EudraCT (2011-003669-14), and the Pan African Clinical Trial Registry (PACTR20121000441277). Results Between July 20, 2012, and Jan 31, 2019, we randomly allocated 12 737 patients with TBI to receive tranexamic acid (6406 [50·3%] or placebo [6331 [49·7%], of whom 9202 (72·2%) patients were treated within 3 h of injury. Among patients treated within 3 h of injury, the risk of head injury-related death was 18·5% in the tranexamic acid group versus 19·8% in the placebo group (855 vs 892 events; risk ratio [RR] 0·94 [95% CI 0·86-1·02]). In the prespecified sensitivity analysis that excluded patients with a GCS score of 3 or bilateral unreactive pupils at baseline, the risk of head injury-related death was 12·5% in the tranexamic acid group versus 14·0% in the placebo group (485 vs 525 events; RR 0·89 [95% CI 0·80-1·00]). The risk of head injury-related death reduced with tranexamic acid in patients with mild-to-moderate head injury (RR 0·78 [95% CI 0·64-0·95]) but not in patients with severe head injury (0·99 [95% CI 0·91-1·07]; p value for heterogeneity 0·030). Early treatment was more effective than was later treatment in patients with mild and moderate head injury (p=0·005) but time to treatment had no obvious effect in patients with severe head injury (p=0·73). The risk of vascular occlusive events was similar in the tranexamic acid and placebo groups (RR 0·98 (0·74-1·28). The risk of seizures was also similar between groups (1·09 [95% CI 0·90-1·33]). Interpretation Our results show that tranexamic acid is safe in patients with TBI and that treatment within 3 h of injury reduces head injury-related death. Patients should be treated as soon as possible after injury. Funding National Institute for Health Research Health Technology Assessment, JP Moulton Charitable Trust, Department of Health and Social Care, Department for International Development, Global Challenges Research Fund, Medical Research Council, and Wellcome Trust (Joint Global Health Trials scheme)

Understanding the neuroprotective effect of tranexamic acid: an exploratory analysis of the CRASH-3 randomised trial

Background: The CRASH-3 trial hypothesised that timely tranexamic acid (TXA) treatment might reduce deaths from intracranial bleeding after traumatic brain injury (TBI). To explore the mechanism of action of TXA in TBI, we examined the timing of its effect on death. Methods: The CRASH-3 trial randomised 9202 patients within 3 h of injury with a GCS score ≤ 12 or intracranial bleeding on CT scan and no significant extracranial bleeding to receive TXA or placebo. We conducted an exploratory analysis of the effects of TXA on all-cause mortality within 24 h of injury and within 28 days, excluding patients with a GCS score of 3 or bilateral unreactive pupils, stratified by severity and country income. We pool data from the CRASH-2 and CRASH-3 trials in a one-step fixed effects individual patient data meta-analysis. Results: There were 7637 patients for analysis after excluding patients with a GCS score of 3 or bilateral unreactive pupils. Of 1112 deaths, 23.3% were within 24 h of injury (early deaths). The risk of early death was reduced with TXA (112 (2.9%) TXA group vs 147 (3.9%) placebo group; risk ratio [RR] RR 0.74, 95% CI 0.58–0.94). There was no evidence of heterogeneity by severity (p = 0.64) or country income (p = 0.68). The risk of death beyond 24 h of injury was similar in the TXA and placebo groups (432 (11.5%) TXA group vs 421 (11.7%) placebo group; RR 0.98, 95% CI 0.69–1.12). The risk of death at 28 days was 14.0% in the TXA group versus 15.1% in the placebo group (544 vs 568 events; RR 0.93, 95% CI 0.83–1.03). When the CRASH-2 and CRASH-3 trial data were pooled, TXA reduced early death (RR 0.78, 95% CI 0.70–0.87) and death within 28 days (RR 0.88, 95% CI 0.82–0.94). Conclusions: Tranexamic acid reduces early deaths in non-moribund TBI patients regardless of TBI severity or country income. The effect of tranexamic acid in patients with isolated TBI is similar to that in polytrauma. Treatment is safe and even severely injured patients appear to benefit when treated soon after injury. Trial registration: ISRCTN15088122, registered on 19 July 2011; NCT01402882, registered on 26 July 2011